

Claims

1. (S)-4-Amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]-pyrimidin-4-yl)piperidine-4-carboxamide, (i.e. Compound (I)), in crystalline form, in the form of Form B.
2. Compound (I) in crystalline form, according to claim 1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern with at least three specific peaks at about 2-theta = 12.3°, 15.0° and 19.2°.
3. Compound (I) in crystalline form, according to claim 1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern with specific peaks at about 2-theta = 10.0, 12.3, 15.0, 17.1, 19.2 and 24.4°.
4. Compound (I) in crystalline form, according to claim 1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern substantially the same as that shown in Figure 3.1.
5. Compound (I) in crystalline form, according to claim 1, in the form of Form B wherein said Form B has an X-ray powder diffraction pattern substantially the same as that shown in Figure 3.2.
6. A pharmaceutical composition which comprises Compound (I) in crystalline form, as claimed in any one of claims 1 to 5, in association with a pharmaceutically-acceptable diluent or carrier.
7. Compound (I) in crystalline form, as claimed in any one of claims 1 to 5, for use as a medicament.
8. The use of Compound (I) in crystalline form, as claimed in any one of claims 1 to 5, for the preparation of a medicament for the treatment of cancer.

9. Use of a therapeutically effective amount of Compound (I) in crystalline form, as claimed in any one of claims 1 to 5 in the manufacture of a medicament for treating breast cancer, prostate cancer, or gastric cancer.
- 5 10. A pharmaceutical composition which comprises Compound (I) in crystalline form as claimed in any one of claims 1 to 5, in association with microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate.
- 10 11. A pharmaceutical tablet which comprises from 50 to 500 mg of Compound (I) in crystalline form as claimed in any one of claims 1 to 5, in association with one or more pharmaceutically acceptable excipients.
- 15 12. A pharmaceutical tablet which comprises from 0.5 to 2% by weight of magnesium stearate, from 2 to 5% by weight of croscarmellose sodium, from 15 to 60% by weight of Compound (I) in crystalline form as claimed in any one of claims 1 to 5, microcrystalline cellulose and mannitol, wherein the relative weights of microcrystalline cellulose and mannitol within the tablet are in a ratio of from 3:1 to 1:1 and wherein the amount of Compound (I) in crystalline form within the tablet is from 50 to 500 mg.

Claims

1. (S)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B which is characterized by an X-ray powder diffraction pattern with peaks at about 2-theta = 10.0, 12.3, 15.0, 17.1, 19.2 and 24.4°. 5
2. (S)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B characterized by an X-ray powder diffraction pattern with at least ten peaks at about 2-theta = 15.0, 19.2, 12.3, 10.0, 17.1, 24.4, 16.4, 26.0, 15.5, and 23.9°. 10
3. (S)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B which is characterized by an X-ray powder diffraction pattern with at least ten peaks at about 2-theta = 10.0, 5.0, 15.0, 19.2, 17.1, 12.3, 24.4, 30.2, 32.3, and 23.3°. 15
4. A pharmaceutical composition comprising (S)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B, according to claim 1, in association with a pharmaceutically-acceptable diluent or carrier. 20
5. A pharmaceutical composition comprising (S)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B, according to claim 2, in association with a pharmaceutically-acceptable diluent or carrier. 25
6. A pharmaceutical composition comprising (S)-4-Amino-*N*-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7*H*-pyrrolo[2,3-*d*]-pyrimidin-4-yl)piperidine-4-carboxamide crystalline Form B, according to claim 3, in association with a pharmaceutically-acceptable diluent or carrier. 30

7. The pharmaceutical composition according to claim 4, further comprising microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate.
- 5 8. The pharmaceutical composition according to claim 5, further comprising microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate.
9. The pharmaceutical composition according to claim 6, further comprising microcrystalline cellulose, mannitol, croscarmellose sodium and magnesium stearate.
- 10 10. A pharmaceutical tablet which comprises from 0.5 to 2% by weight of magnesium stearate, from 2 to 5% by weight of croscarmellose sodium, from 15 to 60% by weight of crystalline Form B according to claim 1, microcrystalline cellulose and mannitol, wherein the relative weights of microcrystalline cellulose and mannitol within the tablet are in a ratio of from 3:1 to 1:1 and wherein the amount of crystalline Form B within the tablet is from 50 to 500 mg.
- 15 11. A pharmaceutical tablet which comprises from 0.5 to 2% by weight of magnesium stearate, from 2 to 5% by weight of croscarmellose sodium, from 15 to 60% by weight of crystalline Form B according to claim 2, microcrystalline cellulose and mannitol, wherein the relative weights of microcrystalline cellulose and mannitol within the tablet are in a ratio of from 3:1 to 1:1 and wherein the amount of crystalline Form B within the tablet is from 50 to 500 mg.
- 20 12. A pharmaceutical tablet which comprises from 0.5 to 2% by weight of magnesium stearate, from 2 to 5% by weight of croscarmellose sodium, from 15 to 60% by weight of crystalline Form B according to claim 3, microcrystalline cellulose and mannitol, wherein the relative weights of microcrystalline cellulose and mannitol within the tablet are in a ratio of from 3:1 to 1:1 and wherein the amount of crystalline Form B within the tablet is from 50 to 500 mg.
- 25 30